Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR7 | P34969 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12084308 | 0.90 | CHRM1 (0.49) | OPRM1OPRK1OPRL1HTR1ACHRM4 | |
| SCHEMBL22472939 | 0.90 | BACE1 (0.46) | OPRM1OPRK1OPRL1HTR1AALDH1A1 | |
| SCHEMBL31288693 | 0.87 | OPRM1 (0.43) | OPRM1OPRK1OPRL1HTR1AALDH1A1 | |
| SCHEMBL22449305 | 0.87 | OPRM1 (0.43) | OPRM1OPRK1OPRL1HTR1AALDH1A1 | |
| SCHEMBL12084233 | 0.83 | CHRM1 (0.53) | OPRM1OPRK1OPRL1ALDH1A1GAA | |
| SCHEMBL12084376 | 0.81 | OPRL1 (0.44) | OPRM1OPRK1OPRL1HTR1ACHRM4 | |
| SCHEMBL13643886 | 0.80 | OPRL1 (0.45) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL13640964 | 0.78 | OPRM1 (0.48) | OPRM1OPRK1OPRL1HTR1AALDH1A1 | |
| SCHEMBL12084263 | 0.78 | OPRL1 (0.48) | OPRM1OPRK1OPRL1HTR1AALDH1A1 | |
| SCHEMBL30507197 | 0.78 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | OPRM1 39/4885OPRK1 141/4885OPRL1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.